Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab for maintaining uveitis suppression (ENDURE)
NCT01032915Phase 3Terminated
- Sponsor
- Novartis
- Start
- Feb 2010
- Primary completion
- Jun 2011
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 3 trial of secukinumab in non-infectious intermediate uveitis, Posterior uveitis (non-infectious), non-infectious panuveitis (NIU), sponsored by Novartis. Started Feb 2010; status: terminated.
02
Drugs
secukinumab
03
Conditions
non-infectious intermediate uveitisPosterior uveitis (non-infectious)non-infectious panuveitis (NIU)
Beyond the preview
Go deeper on NCT01032915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01032915.